Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Net Cash Flow (2019 - 2025)

aTYR PHARMA's Net Cash Flow history spans 7 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 1188.89% year-over-year to $4.1 million; the TTM value through Dec 2025 reached -$1.0 million, up 91.45%, while the annual FY2025 figure was -$1.0 million, 91.45% up from the prior year.
  • Net Cash Flow reached $4.1 million in Q4 2025 per ATYR's latest filing, up from -$11.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $57.6 million in Q3 2021 to a low of -$57.4 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$198700.0, with a median of -$349500.0 recorded in 2024.
  • Peak YoY movement for Net Cash Flow: plummeted 4687.82% in 2021, then soared 2375.39% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$57.4 million in 2021, then soared by 87.02% to -$7.5 million in 2022, then soared by 271.63% to $12.8 million in 2023, then tumbled by 102.96% to -$378000.0 in 2024, then soared by 1188.89% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Net Cash Flow are $4.1 million (Q4 2025), -$11.2 million (Q3 2025), and $7.3 million (Q2 2025).